First High Yield Opportunities 2027 Term Fund (FTHY) vs abrdn Life Sciences Investors (HQL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
abrdn Life Sciences Investors (HQL) has outperformed First High Yield Opportunities 2027 Term Fund (FTHY) over the past year, gaining 11.2% versus a loss of 11.2%. Over five years, HQL leads with a -15.0% price change compared with -39.0% for FTHY. On valuation, abrdn Life Sciences Investors trades at a lower trailing P/E (2.6x vs 18.4x for First High Yield Opportunities 2027 Term Fund).
abrdn Life Sciences Investors pays a dividend yielding 10.88%, while First High Yield Opportunities 2027 Term Fund does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTHY | HQL |
|---|---|---|
| Share price | $12.70 | $17.56 |
| Market cap | $467.02M | — |
| 1-day change | -0.24% | 0.00% |
| YTD return | -9.74% | +4.65% |
| 1-year return | -11.19% | +11.21% |
| 5-year return | -39.00% | -15.00% |
| P/E ratio (TTM) | 18.41 | 2.64 |
| EPS (TTM) | $0.69 | $6.64 |
| Dividend yield | 11.81% | 10.88% |
| Annual dividend | $0.00 | $1.91 |
| 52-week high | $14.42 | $22.67 |
| 52-week low | $12.54 | $15.66 |
| Distance from 52-week high | -11.93% | -22.54% |
| Average volume | 105.76K | 148.17K |
| Shares outstanding | 36.77M | — |
| Sector | Financial Services | Financial Services |
| Industry | Asset Management | Asset Management |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HQL has outperformed FTHY by 22.4 percentage points over the past year.
- First High Yield Opportunities 2027 Term Fund trades at a higher earnings multiple (18.4x vs 2.6x trailing P/E).
About abrdn Life Sciences Investors
HQL stock →Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.
Financial Services · Asset Management
FTHY vs HQL FAQ
Which stock has performed better over the past year, FTHY or HQL?
HQL returned +11.21% over the past 12 months, compared with -11.19% for FTHY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, FTHY or HQL?
HQL has the lower trailing P/E at 2.6, versus 18.4 for FTHY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, First High Yield Opportunities 2027 Term Fund or abrdn Life Sciences Investors?
First High Yield Opportunities 2027 Term Fund has the higher yield at 11.81%, compared with 10.88% for abrdn Life Sciences Investors.
Are First High Yield Opportunities 2027 Term Fund and abrdn Life Sciences Investors in the same industry?
Yes. Both are classified in the Asset Management industry within the Financial Services sector.